| Literature DB >> 35948029 |
Robert I Haddad1, Lindsay Bischoff2, Douglas Ball3, Victor Bernet4, Erik Blomain5, Naifa Lamki Busaidy6, Michael Campbell7, Paxton Dickson8, Quan-Yang Duh9, Hormoz Ehya10, Whitney S Goldner11, Theresa Guo12, Megan Haymart13, Shelby Holt14, Jason P Hunt15, Andrei Iagaru5, Fouad Kandeel16, Dominick M Lamonica17, Susan Mandel18, Stephanie Markovina19, Bryan McIver20, Christopher D Raeburn21, Rod Rezaee22, John A Ridge10, Mara Y Roth23, Randall P Scheri24, Jatin P Shah25, Jennifer A Sipos26, Rebecca Sippel27, Cord Sturgeon28, Thomas N Wang29, Lori J Wirth30, Richard J Wong25, Michael Yeh31, Carly J Cassara32, Susan Darlow32.
Abstract
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).Entities:
Mesh：
Substances：
Year: 2022 PMID： 35948029 DOI： 10.6004/jnccn.2022.0040
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 12.693